Stay updated on Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial

Sign up to get notified when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    - Removed version v3.1.0 and added a new version tag v3.2.0 along with an important notice about government funding and operating status of the NIH Clinical Center.
    Difference
    1%
    Check dated 2025-10-05T17:37:22.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Update includes a new version tag (v3.1.0) and removal of several MedlinePlus topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs), indicating a content scope reduction with a new release.
    Difference
    0.2%
    Check dated 2025-09-28T11:17:47.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    35 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2; the Back to Top element was removed.
    Difference
    0.1%
    Check dated 2025-09-14T00:47:59.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1.
    Difference
    0.1%
    Check dated 2025-09-06T21:32:17.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the addition of new facility names and locations, as well as a publication related to dupilumab, while several previous location entries and drug information have been removed.
    Difference
    5%
    Check dated 2025-08-30T15:58:39.000Z thumbnail image
  8. Check
    57 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the latest results of a study on dupilumab for chronic spontaneous urticaria (CSU), including new efficacy data and participant demographics. Notably, the number of study locations has decreased from 101 to 98, and the results posting date has been updated to August 20, 2025.
    Difference
    100%
    Check dated 2025-08-23T14:23:41.000Z thumbnail image

Stay in the know with updates to Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.